Study of Ischemia Modified Albumin as a Biomarker in Acute Ischaemic Stroke

Background and Purpose: Stroke is one of the leading causes of mortality and long-term disability. Prompt diagnosis and treatment of stroke are crucial for a better outcome. A blood test, which serves as a biomarker in rural areas will help in immediately transferring patients to a hospital for thrombolytic therapy. The aim of the present study was to examine the role of ischemia modified albumin (IMA) as a screening biomarker in acute ischaemic stroke. Materials and Methods: Serum samples were collected from 50 patients with acute ischaemic stroke within one, 24, 48, 72 and 144 h of time of admission for IMA. We compared patients' 1st-hour value with age-and sex-matched controls by independent sample t test. p value < 0.05 was considered significant. Results: The serum IMA levels of patients 1st hour (108 +/- 8.9) were significantly higher than those of the controls (79 +/- 6.3) p < 0.05. The IMA levels showed a steady decline at 1 h (108 +/- 8.9), 24 h (94 +/- 4.2), 48 h (82 +/- 6.1), 72 h (77 +/- 5.6) and 144 h (76 +/- 3.8) of admission in patients. Conclusion: We observed that serum IMA was significantly higher in stroke patients as compared to controls. IMA was elevated in the acute phase of stroke and had a gradual graded decline over 1 week. We concluded that IMA may be a sensitive and rapid biomarker for screening of early ischaemic stroke in rural settings. (C) 2018 S. Karger AG, Basel